期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

安罗替尼三线治疗非小细胞肺癌的疗效及安全性分析 被引量：4

原文传递
导出
摘要 目的探讨安罗替尼三线治疗非小细胞肺癌(NSCLC)的临床疗效及安全性。方法选择晚期NSCLC患者20例,采用安罗替尼三线治疗,12.5mg/次,1次/d,连续用药2周停药1周(21d)为1个周期。观察近期疗效,随访统计无进展生存期(PFS)和药物毒副作用。结果20例患者完成了2~6个周期的治疗,0例CR,3例PR,8例SD,9例PD,总有效率为15.00%,疾病控制率为55.00%。治疗期间,不良反应主要为恶心呕吐(65.00%)、食欲减退(60.00%)、腹泻(10.00%)、白细胞下降(35.00%)、肝功能异常(5.00%)、肾功能异常(5.00%)、血栓栓塞(5.00%)、咯血(10.00%)、口腔黏膜炎(20.00%),除1例血栓栓塞为Ⅲ级反应外,其余均为Ⅰ~Ⅱ级轻-中度反应。随访显示,患者的中位PFS为4.02个月(95%CI2.3~12.1)。结论安罗替尼三线治疗晚期NSCLC能够带来一定的OS和PFS获益,且用药安全性较好,可作为多线化疗失败后NSCLC的新选择。
作者 薛百兴 邝先奎
机构地区 河南省项城市第一人民医院
出处 《首都食品与医药》 2020年第3期107-108,共2页 Capital Food Medicine
关键词 非小细胞肺癌 安罗替尼 三线方案 临床疗效 安全性
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献6

二级参考文献21

  • 1Fidias P, Dakhil S, Lyss A, et al. Phase Ⅲ study of immediate ver- sus delayed docetaxel after induction therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer: updated report with survival[ J ]. J Clin Oncol, 2009, 27 (4) : 591-598.
  • 2Belani CP, Brodowicz T, Ciuleanu TE, et al. Quality of life in pa- tients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN) : resultsfrom a randomised, double-blind, phase 3 study [ J]. Lancet Oncol, 2012,13(3) : 292-299. DOI: 10. 1016/S1470-2045(11)70339-4.
  • 3Paz-Ares LG, de Marinis F, Dediu M, et al. PARAMOUNT: Final overall survival results of the phase Ⅲ study of maintenance peme- trexed versus placebo immediately after induction treatment with pem- etrexed plus cisplafin for advanced nonsquamous non-small-cell lung cancer[J]. J Clin Oncol, 2013, 31 (23) : 2895-2902. DOI: 10. 1200/JC0,2012.47. 1102.
  • 4Perol M, Chouaid C, Perol D, et al. Randomized, phase HI study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induc- tion chemotherapy in advanced non-small-cell lung cancer[ J].J Clin Oncol, 2012, 30(28): 3516-3524. DOI: 10, 1200/JGO. 2011.39. 9782.
  • 5Zhang L, Ma S, Song X, et al. Gefitinib versus placebo as mainte- nance therapy in patients with locally advanced or metastatic non- small-cell lung cancer ( INFORM ; C-TONG 0804 ) : a multicentre, double-blind randomised phase 3 trial [ J]. Lancet Oncol, 2012, 13 (5) : 466-475. DOI: 10. 1016/S1470-2045(12)70117-1.
  • 6Zhao H, Fan Y, Ma S, et al. Final overall survival results from a phase Ⅲ, randomized, placebo-controlled, parallei-goup study of gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C- TONG 0804) [J]. J Thorac Oncol, 2015, 10(4) : 655-664. DOI: 10. 1097/JTO. 0000000000000445.
  • 7Crinb L, Dansin E, Garrido P, et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small- cell lung cancer (SAIL, MO19390) : a phase 4 study[J]. Lancet Oncol, 2010, 11 (8) :733-740. DOI: 10. 1016/S1470-2045 (10) 70151-0.
  • 8Barlesi F, Scherpereel A, Rittmeyer A, et al. Randomized phase Ⅲ trial of maintenance bevacizumab with or without pemetrexed after firstline induction with bevacizumab, cisplatin, and pemetrexed inadvanced nonsquamous non-small-cell lung cancer: AVAPERL (M022089) [J]. J Clin Oncol, 2013, 31(24) : 3004-3011. DOI: 10. 1200/JCO. 2012.42. 3749.
  • 9Pirker R, Pereira JR, Szczesma A, et al. Cetuximab plus chemo- therapy in patients with advanced non-small-cell hmg cancer (FLEX) : an open-label randomized phase Ⅲ trial [ J ]. Lancet, 2009, 373(9674): 1525-1531. DOI: 10. 1016/S0140-6736(09) 60569-9,.
  • 10Shi SB, Ma TH, Li CHet al. Effect of maintenance therapy With dendritic cells: cytokine-induced killer cells in patients with advanced non-small cell lung cancer[ J]. Tumori, 2012, 98 ( 3 ) : 314-319. DOI: 10. 1700/1125. 12398.

共引文献1411

同被引文献39

引证文献4

二级引证文献12

首都食品与医药
2020年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部